Paresthesia Treatment Market By Disease Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global paresthesia treatment market was valued at $5,376.28 million in 2021, and is projected to reach $7,900.0 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.

Paresthesia is numbness and a burning feeling that occurs most often in the extremities, such as the hands, arms, legs, or feet. It can occur elsewhere in the body as well. It is the same "pins and needles" feeling that happens when someone sits on their leg or foot for too long. It is caused when the nerves of arms and legs are under any kind of pressure. The discomfort goes away, once that pressure is relieved. Some people may have chronic paresthesia, which could be a sign of a more serious nerve injury or condition. Some of the causes of paresthesia include stroke, multiple sclerosis, tumor in the spinal cord or brain, high levels of vitamin D or other vitamins, diabetes, fibromyalgia, high blood pressure, infection, nerve injury, and compressed or pinched nerve. The symptoms of paresthesia include tingling or a "pins and needles" sensation, aching or burning pain, numbness or poor feeling in the affected area, a feeling that the affected area has "fallen asleep", prickling or itching feeling, and hot or cold skin.

The global paresthesia treatment market is anticipated to show significant market growth during the forecast period, owing to rise in the prevalence of disease such as cancer, surge in geriatric population, and lack of proper nutrients in the food. Furthermore, increase in prevalence of paresthesia among the population, poor lifestyle, and surge in healthcare expenditure considerably contribute toward the market growth. However, low effectiveness of medicines associated with the treatment and stringent regulatory rules of the authority for the approvals of the medicines negatively impact the market growth. Conversely, the surge in investments in the research and developments (R&Ds) for better treatment offers lucrative opportunities for the growth of the market.

The paresthesia treatment market is segmented on the basis of disease type, treatment, distribution channel, and region. By disease type, the market is bifurcated into acute paresthesia and chronic paresthesia. Furthermore, the acute paresthesia is sub-classified as pediatric and adult. The chronic paresthesia segment is sub-classified as pediatric and adult. By treatment, the market is fragmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include: Abbott Laboratories, AbbVie Inc., Baxter International Inc., Bio-Medical Research Ltd., Boston Scientific Corporation, Cipla Ltd., Cyberonics, Inc., GlaxoSmithKline plc., Glenmark Pharmaceuticals, Medtronic plc, Merck KGaA, NeuroBo Pharmaceuticals, Inc., Nevro Corporation, Omron Healthcare, Inc. , Pfizer Inc., Reshape Lifesciences Inc., and Stimwave, LLC.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the paresthesia treatment market analysis from 2021 to 2031 to identify the prevailing paresthesia treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the paresthesia treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global paresthesia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Acute Paresthesia
- Age Group
- Adult
- Geriatric
Chronic Paresthesia
- Age Group
- Adult
- Geriatric

By Treatment

Immunosuppressant
Anticonvulsants
Topical Creams
Antivirals
Others

By Distribution Channel

Online Pharmacy
Hospital Pharmacy
Retail Pharmacy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Spain
- Rest of Europe
- France
- Germany
- UK
- Italy
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest Of Asia Pacific
LAMEA
- Brazil
- Turkey
- Venezuela
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- AbbVie Inc.
- Baxter International Inc.
- Bio-Medical Research Ltd.
- Boston Scientific Corporation
- Cipla Ltd.
- Cyberonics, Inc.
- EnteroMedics Inc.
- GlaxoSmithKline plc.
- Glenmark
- Medtronic
- Merck
- Nevro Corp.
- Omron Healthcare, Inc.
- Pfizer
- Stimwave LLC
- Stryker Corp.

Product Code: A17080

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Acute Paresthesia
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Acute Paresthesia Paresthesia Treatment Market by Age Group
4.3 Chronic Paresthesia
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Chronic Paresthesia Paresthesia Treatment Market by Age Group

CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Immunosuppressant
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Anticonvulsants
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Topical Creams
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Antivirals
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
5.6 Others
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country

CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Disease Type
  - 7.2.5.1.2 Market size and forecast, by Treatment
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Disease Type
  - 7.2.5.2.2 Market size and forecast, by Treatment
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Disease Type
  - 7.2.5.3.2 Market size and forecast, by Treatment
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 France
  - 7.3.5.1.1 Market size and forecast, by Disease Type
  - 7.3.5.1.2 Market size and forecast, by Treatment
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 Germany
  - 7.3.5.2.1 Market size and forecast, by Disease Type
  - 7.3.5.2.2 Market size and forecast, by Treatment
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Disease Type
  - 7.3.5.3.2 Market size and forecast, by Treatment
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Disease Type
  - 7.3.5.4.2 Market size and forecast, by Treatment
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Disease Type
  - 7.3.5.5.2 Market size and forecast, by Treatment
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Disease Type
  - 7.3.5.6.2 Market size and forecast, by Treatment
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Disease Type
  - 7.4.5.1.2 Market size and forecast, by Treatment
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Disease Type
  - 7.4.5.2.2 Market size and forecast, by Treatment
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Disease Type
  - 7.4.5.3.2 Market size and forecast, by Treatment
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Disease Type
  - 7.4.5.4.2 Market size and forecast, by Treatment
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Disease Type
  - 7.4.5.5.2 Market size and forecast, by Treatment
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Taiwan
  - 7.4.5.6.1 Market size and forecast, by Disease Type
  - 7.4.5.6.2 Market size and forecast, by Treatment
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
  - 7.4.5.7 Rest Of Asia Pacific
  - 7.4.5.7.1 Market size and forecast, by Disease Type
  - 7.4.5.7.2 Market size and forecast, by Treatment
  - 7.4.5.7.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Disease Type
  - 7.5.5.1.2 Market size and forecast, by Treatment
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Turkey
  - 7.5.5.2.1 Market size and forecast, by Disease Type
  - 7.5.5.2.2 Market size and forecast, by Treatment
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 Venezuela
  - 7.5.5.3.1 Market size and forecast, by Disease Type
  - 7.5.5.3.2 Market size and forecast, by Treatment
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Saudi Arabia
  - 7.5.5.4.1 Market size and forecast, by Disease Type
  - 7.5.5.4.2 Market size and forecast, by Treatment
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel
  - 7.5.5.5 South Africa
  - 7.5.5.5.1 Market size and forecast, by Disease Type
  - 7.5.5.5.2 Market size and forecast, by Treatment
  - 7.5.5.5.3 Market size and forecast, by Distribution Channel
  - 7.5.5.6 Rest of LAMEA
  - 7.5.5.6.1 Market size and forecast, by Disease Type
  - 7.5.5.6.2 Market size and forecast, by Treatment
  - 7.5.5.6.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 AbbVie Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Baxter International Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Bio-Medical Research Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Boston Scientific Corporation
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Cipla Ltd.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Cyberonics, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 EnteroMedics Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 GlaxoSmithKline plc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Glenmark
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Medtronic
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Merck
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
9.13 Nevro Corp.
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
9.14 Omron Healthcare, Inc.
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
9.15 Pfizer
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
9.16 Stimwave LLC
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
9.17 Stryker Corp.
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments